YMAB Stock Overview
A commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Y-mAbs Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.28 |
| 52 Week High | US$20.90 |
| 52 Week Low | US$6.48 |
| Beta | 0.61 |
| 1 Month Change | -20.46% |
| 3 Month Change | -36.60% |
| 1 Year Change | 21.94% |
| 3 Year Change | -53.09% |
| 5 Year Change | -73.57% |
| Change since IPO | -65.50% |
Recent News & Updates
We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth
Dec 10
The Market Doesn't Like What It Sees From Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Revenues Yet As Shares Tumble 26%
Nov 19Y-mAbs Therapeutics: Slow But Steady Prospect In Rare Cancers
Oct 21Recent updates
We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth
Dec 10The Market Doesn't Like What It Sees From Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Revenues Yet As Shares Tumble 26%
Nov 19Y-mAbs Therapeutics: Slow But Steady Prospect In Rare Cancers
Oct 21Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Held Back By Insufficient Growth Even After Shares Climb 33%
Sep 12Revisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade)
Aug 12We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn
Jul 15Investors Don't See Light At End Of Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Tunnel And Push Stock Down 29%
Jun 02Y-mAbs: There's A Ceiling Here Somewhere
May 09We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn
Mar 14Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry
Feb 17Y-mAbs Therapeutics: A Monoclonal Antibody Play
Jan 14We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate
Nov 13We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth
Jul 16Party Time: Brokers Just Made Major Increases To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Earnings Forecasts
May 13Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Price Is Right But Growth Is Lacking After Shares Rocket 104%
Apr 17Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely
Mar 22We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Needs To Drive Business Growth Carefully
Dec 13Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically
Aug 13Y-mAbs gets FDA nod to begin phase 1 study of GD2-SADA for certain cancers
Jul 12Y-mAbs Therapeutics: Steady, Small Steps Targeting Rare Cancers
May 30Shareholder Returns
| YMAB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -12.2% | -3.6% | -2.4% |
| 1Y | 21.9% | -2.6% | 23.4% |
Return vs Industry: YMAB exceeded the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: YMAB underperformed the US Market which returned 23.3% over the past year.
Price Volatility
| YMAB volatility | |
|---|---|
| YMAB Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: YMAB has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: YMAB's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 100 | Mike Rossi | www.ymabs.com |
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform.
Y-mAbs Therapeutics, Inc. Fundamentals Summary
| YMAB fundamental statistics | |
|---|---|
| Market cap | US$370.85m |
| Earnings (TTM) | -US$23.86m |
| Revenue (TTM) | US$84.55m |
4.4x
P/S Ratio-15.5x
P/E RatioIs YMAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| YMAB income statement (TTM) | |
|---|---|
| Revenue | US$84.55m |
| Cost of Revenue | US$9.45m |
| Gross Profit | US$75.11m |
| Other Expenses | US$98.97m |
| Earnings | -US$23.86m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.53 |
| Gross Margin | 88.83% |
| Net Profit Margin | -28.22% |
| Debt/Equity Ratio | 0% |
How did YMAB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 03:16 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Y-mAbs Therapeutics, Inc. is covered by 21 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Evan Seigerman | BMO Capital Markets Equity Research |
| Etzer Darout | BMO Capital Markets Equity Research |